NCT06554028 2024-08-14Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal CancerHenan Cancer HospitalPhase 2 Not yet recruiting46 enrolled